Literature DB >> 26489624

Angiogenic factors are associated with development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Di-Min Nie1, Qiu-Ling Wu1, Xia-Xia Zhu1, Ran Zhang1, Peng Zheng1, Jun Fang1, Yong You1, Zhao-Dong Zhong1, Ling-Hui Xia1, Mei Hong2.   

Abstract

Acute graft-versus-host disease (aGVHD) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the mechanisms of aGVHD are not well understood. We aim to investigate the roles of the three angiogenic factors: angiopoietin-1 (Ang-1), Ang-2 and vascular endothelial growth factor (VEGF) in the development of aGVHD. Twenty-one patients who underwent allo-HSCT were included in our study. The dynamic changes of Ang-1, Ang-2 and VEGF were monitored in patients before and after allo-HSCT. In vitro, endothelial cells (ECs) were treated with TNF-β in the presence or absence of Ang-1, and then the Ang-2 level in the cell culture medium and the tubule formation by ECs were evaluated. After allo-HSCT, Ang-1, Ang-2 and VEGF all exhibited significant variation, suggesting these factors might be involved in the endothelial damage in transplantation. Patients with aGVHD had lower Ang-1 level at day 7 but higher Ang-2 level at day 21 than those without aGVHD, implying that Ang-1 may play a protective role in early phase yet Ang-2 is a promotion factor to aGVHD. In vitro, TNF-β promoted the release of Ang-2 by ECs and impaired tubule formation of ECs, which were both weakened by Ang-1, suggesting that Ang-1 may play a protective role in aGVHD by influencing the secretion of Ang-2, consistent with our in vivo tests. It is concluded that monitoring changes of these factors following allo-HSCT might help to identify patients at a high risk for aGVHD.

Entities:  

Keywords:  acute graft-versus-host disease; allogeneic hematopoietic stem cell transplantation; angiogenic factors; endothelial damage

Mesh:

Substances:

Year:  2015        PMID: 26489624     DOI: 10.1007/s11596-015-1492-4

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  43 in total

1.  Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.

Authors:  Thomas Luft; Sascha Dietrich; Christine Falk; Michael Conzelmann; Michael Hess; Axel Benner; Frank Neumann; Berend Isermann; Ute Hegenbart; Anthony D Ho; Peter Dreger
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

2.  Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.

Authors:  C-K Min; S Y Kim; M J Lee; K S Eom; Y J Kim; H J Kim; S Lee; S G Cho; D W Kim; J W Lee; W S Min; C C Kim; C S Cho
Journal:  Bone Marrow Transplant       Date:  2006-06-05       Impact factor: 5.483

Review 3.  Angiopoietins: a link between angiogenesis and inflammation.

Authors:  Ulrike Fiedler; Hellmut G Augustin
Journal:  Trends Immunol       Date:  2006-10-12       Impact factor: 16.687

4.  Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease.

Authors:  R A Lunn; N Sumar; A S Bansal; J Treleaven
Journal:  Hematology       Date:  2005-04       Impact factor: 2.269

5.  Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive.

Authors:  Yuji Oshima; Sachiko Oshima; Hiroyuki Nambu; Shu Kachi; Kyoichi Takahashi; Naoyasu Umeda; JiKui Shen; Aling Dong; Rajendra S Apte; Elia Duh; Sean F Hackett; Godwin Okoye; Kazuki Ishibashi; James Handa; Michele Melia; Stanley Wiegand; George Yancopoulos; Donald J Zack; Peter A Campochiaro
Journal:  FASEB J       Date:  2005-03-31       Impact factor: 5.191

6.  Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease.

Authors:  C Salat; E Holler; H J Kolb; R Pihusch; B Reinhardt; E Hiller
Journal:  Bone Marrow Transplant       Date:  1997-05       Impact factor: 5.483

7.  Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease.

Authors:  Dong Hwan Kim; Nan Young Lee; Myung-Hoon Lee; Sang Kyun Sohn
Journal:  Biol Blood Marrow Transplant       Date:  2008-12       Impact factor: 5.742

Review 8.  Angiopoietin-1 in the treatment of ischemia and sepsis.

Authors:  Nathan M Novotny; Tim Lahm; Troy A Markel; Paul R Crisostomo; Meijing Wang; Yue Wang; Jiangning Tan; Daniel R Meldrum
Journal:  Shock       Date:  2009-04       Impact factor: 3.454

Review 9.  Vascular endothelium as 'novel' target of graft-versus-host disease.

Authors:  André Tichelli; Alois Gratwohl
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

10.  Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.

Authors:  Ivan S Moiseev; Sergey V Lapin; Elena A Surkova; Margarita Y Lerner; Vladimir N Vavilov; Boris V Afanasyev
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-10       Impact factor: 5.742

View more
  3 in total

1.  Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Jie-Ke Cui; Yin Xiao; Yong You; Wei Shi; Qing Li; Yi Luo; Lin Jiang; Zhao-Dong Zhong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

2.  Application of latent class analysis in diagnosis of graft-versus-host disease by serum markers after allogeneic haematopoietic stem cell transplantation.

Authors:  Maedeh Amini; Anoshirvan Kazemnejad; Aliakbar Rasekhi; Farid Zayeri; Abbas Hajifathali; Farzaneh Tavakoli
Journal:  Sci Rep       Date:  2020-02-27       Impact factor: 4.379

3.  Synergistic Effects of Controlled-Released BMP-2 and VEGF from nHAC/PLGAs Scaffold on Osteogenesis.

Authors:  Ting Wang; Shu Guo; Hua Zhang
Journal:  Biomed Res Int       Date:  2018-09-24       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.